Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control

Climb Bio, Inc.

Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.
Three of four patients required no further immunosuppressive treatment after up to 4 doses.
No treatment-related adverse events grade 3 or higher observed in the Phase 1b trial (NCT04652570).
Data support continued development of budoprutug for B-cell mediated diseases.
Company remains focused on advancing its pipeline; risks include clinical and regulatory uncertainties.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.